NCT03544905 2025-04-22
Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33
Haihe Biopharma Co., Ltd.
Phase 1 Completed
Clinical Trials
15 trialsNCT03965845 2022-09-19
A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
Calithera Biosciences, Inc
Phase 1/2 Completed
NCT02045017 2021-08-27
Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency
Celgene
Phase 2 Completed
NCT01976741 2021-05-06
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
Bayer
Phase 1 Completed
NCT01865747 2021-04-27
METEOR
Exelixis
Phase 3 Completed
NCT01149720 2019-02-12
Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Completed
NCT01943864 2017-05-31
A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers
GlaxoSmithKline
Phase 2 Completed
NCT02536391 2016-11-02
Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects
Genentech, Inc.
Phase 1 Completed
NCT00941863 2016-03-22
Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)
Bayer
Phase 1 Completed
NCT02563951 2016-01-08
Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers
Maxinase Life Sciences Ltd.
Phase 1 Completed
NCT01563055 2015-08-10
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 2 Completed
NCT01808326 2015-06-22
A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 2 Completed
NCT01697020 2013-12-02
Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions
Nova Laboratories Limited
Phase 1 Completed
NCT00080080 2007-06-08
Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer
Point Therapeutics
Phase 2 Completed
NCT00083239 2007-06-08
Study of Talabostat in Advanced Melanoma
Point Therapeutics
Phase 2 Completed